Literature DB >> 1455124

DQB1-0602 (DQw1) is not present in most nonDR2 Caucasian narcoleptics.

E Mignot1, X Lin, J Kalil, C George, S Singh, M Billiard, J Montplaisir, J Arrigoni, C Guilleminault, W C Dement.   

Abstract

Human narcolepsy is a genetically determined disorder of sleep strongly associated with the human leucocyte antigens (HLA) DR2 and DQw1. In black narcoleptic patients, susceptibility for narcolepsy is more closely related to a specific gene subtype of DQw1, DQB1-0602, than to DR2. About 30% of black narcoleptic patients are nonDR2, but all carry the HLA DQB1-0602 gene. In the present study, we have tested caucasian nonDR2 cataplectic patients (6 sporadic cases and 7 familial cases from 3 multiplex families) for the presence of the HLA DQB1-0602 and DQA1-0102 (DQw1) using a specific polymerase chain reaction (PCR)-oligotyping technique. None of the patients was DQB1-0602 or DQA1-0102 positive, thus proving that, in caucasians, DQB1-0602 and DQA1-0102 (DQw1) are not prerequisites for the diagnosis of narcolepsy. Further studies with more patients are warranted to exclude the possibility that a few caucasian patients carry rare haplotypes with DQB1-0602 independently of DR2.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1455124     DOI: 10.1093/sleep/15.5.415

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  4 in total

1.  Dual cases of type 1 narcolepsy with schizophrenia and other psychotic disorders.

Authors:  Francesca Canellas; Ling Lin; Maria Rosa Julià; Antonio Clemente; Cristofol Vives-Bauza; Hanna M Ollila; Seung Chul Hong; Susana M Arboleya; Mali A Einen; Juliette Faraco; Marcelo Fernandez-Vina; Emmanuel Mignot
Journal:  J Clin Sleep Med       Date:  2014-09-15       Impact factor: 4.062

Review 2.  Benefits and risks of pharmacotherapy for narcolepsy.

Authors:  Merrill M Mitler; Roza Hayduk
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  IgH (mu-switch and gamma-1) region restriction fragment length polymorphism in human narcolepsy.

Authors:  S M Singh; C F George; R N Ott; C Rattazzi; C Guilleminault; W C Dement; E Mignot
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

4.  Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.

Authors:  Jacques Montplaisir; Dominique Petit; Marie-Josée Quinn; Manale Ouakki; Geneviève Deceuninck; Alex Desautels; Emmanuel Mignot; Philippe De Wals
Journal:  PLoS One       Date:  2014-09-29       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.